Lantus (insulin glargine) / Sanofi 
Welcome,         Profile    Billing    Logout  
 89 Diseases   30 Trials   30 Trials   3067 News 


«12...89101112131415161718...2829»
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Diagnosis of neonatal diabetes with rare PDX1-mutation (Green Room) -  Jan 4, 2020 - Abstract #WSMRF2020WSMRF_393;    
    The clinical course of neonatal diabetes depends on the genotype. In this case, the infant presented with persistent hyperglycemia requiring basal-bolus regimen, but the mild phenotype allowed the patient to be successfully weaned off insulin.
  • ||||||||||  EUGLYCEMIC DIABETIC KETOACIDOSIS (EDKA) IN A (HNFN1A)-MODY PATIENT ON TREATMENT WITH DAPAGLIFLOZIN AND DULAGLUTIDE (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_599;    
    Due to peripheral edema, her treatment changed from pioglitazone 45 mg/d, metformin 2000 mg/d and glimepiride 6 mg/d to dapagliflozin/metformin 10/2000/d and dulaglutide 1,5 mg/qw...After acid-base balance and dehydration were restored, and any infection or concomitant illness were excluded, she was discharged two days later, on treatment with insulin glargine 12 iu/d, metformin 2000mg/d and glimepiride 6mg/d...Futhermore, the prone to ketogenesis diet with reduced calories might have played a precipitating role. Clinicians should use SGLT2i with great caution in (HNFN1A)-MODY patients.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    COMPARISON OF EFFECTS WHEN SWITCHING LONG-ACTING INSULIN: RANDOMISED CROSSOVER STUDY (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_350;    
    The others endpoints weren’t significantly different between pGtoD and pDtoG (table). Conclusions Day-to-day glycaemic variability between day2 and day3 was lower in pGtoD than in pDtoG.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    COMPARISON OF TWO PREGNANCIES OF A WOMAN WITH TYPE 1 DIABETES WITHOUT AND WITH AAPS (ANDROID ARTIFICIAL PANCREAS SYSTEM) SUPPORT (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_318;    
    Methods A woman with 30 years of T1D underwent two subsequent pregnancies: Pregnancy one at age 35 using multiple daily injections (MDI) therapy (insulin glargine, Sanofi and insulin lispro, Eli-Lilly) with flash glucose monitoring (FGM; Abbott Libre Flash)...Conclusions AAPS in pregnant women with T1D can improve metabolic control at reduced risk of hypoglycaemia leading to substantially improved quality of life. Pregnant women with T1D are not willing to wait for commercially available closed loop systems.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Insulin - A century of progress leading to the ultra long-acting insulin analogs (Madrid) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_18;    
    Glargine U-300 may be non-inferior or superior during the titration phase. Degludec is particularly efficacious and safe during the maintenance phase, after initial titration.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Journal:  Physico-chemical stability of co-formulation of PEGylated human amylin with insulin. (Pubmed Central) -  Dec 26, 2019   
    When hAmy-PEG5k (100 or 500 µg/mL) was added to the commercial formulations of either insulin glargine or detemir (95 IU/mL), the combinations remained stable after 6 months stored at 4 °C, as probed by ThT, dynamic light scattering (DLS) measurements and high performance liquid chromatography (HPLC) analyses, confirming the absence of amyloid fibers, minor aggregation products or loss of material. These results suggest hAmy-PEG5k and the insulin analogs glargine and detemir are physicochemically compatible and are candidate ready-to-use fixed-dose combinations.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
    Clinical, Journal:  Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population. (Pubmed Central) -  Dec 23, 2019   
    ITAS is the first study to compare two different managers (nurse-assisted patient vs physician) of the same titration algorithm of Gla-300 in insulin naïve patients with T2DM in unsatisfactory glucose control. This study might provide novel evidence on the efficacy/effectiveness of patient-managed titration algorithm of Gla-300 in a pragmatic setting and may reduce barriers to basal insulin initiation and its titration.
  • ||||||||||  metformin / Generic mfg., Lantus (insulin glargine) / Sanofi, Januvia (sitagliptin) / Merck (MSD)
    Clinical, Journal:  Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes. (Pubmed Central) -  Dec 23, 2019   
    This study might provide novel evidence on the efficacy/effectiveness of patient-managed titration algorithm of Gla-300 in a pragmatic setting and may reduce barriers to basal insulin initiation and its titration. Sitagliptin added to combined metformin and insulin therapy showed greater efficacy and good safety regarding hypoglycemia in patients with newly diagnosed T2DM compared with voglibose.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Humalog pen (insulin lispro) / Eli Lilly
    Trial completion date, Trial primary completion date:  REMIT-DM: Remission Through Early Monitored Insulin Therapy - Duration Month (clinicaltrials.gov) -  Dec 18, 2019   
    P4,  N=10, Active, not recruiting, 
    In patients with T2D inadequately controlled on basal insulin, iGlarLixi offers an effective alternative to BB regimen for reducing HbA1c, without increased risk of hypoglycemia and weight gain. Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: Sep 2019 --> Oct 2020
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Imfinzi (durvalumab) / AstraZeneca, BMS, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. (Pubmed Central) -  Dec 13, 2019   
    Treatment with levothyroxine was commenced after excluding adrenal insufficiency (early morning cortisol: 339 nmol/L) and hypophysitis (normal pituitary on MRI)...Regular blood glucose levels should be performed on routine pathology on all patients on immune checkpoint inhibitor. Clinician awareness of immunotherapy-related diabetes needs to increase in an attempt to detect hyperglycaemia early and prevent DKA.
  • ||||||||||  Soliqua 100/33 (lixisenatide + insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi
    Clinical, Journal:  EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES. (Pubmed Central) -  Nov 29, 2019   
    P3
    Nevertheless, in both trials, a greater proportion of patients taking iGlarLixi than iGlar reached the composite efficacy endpoints of target A1C without hypoglycemia, and target A1C without weight gain, regardless of ethnicity. These results indicate that iGlarLixi is a viable therapeutic option for both Hispanic and NHW patients with T2D, as it is efficacious without a significant increase in hypoglycemia, irrespective of ethnicity.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Journal:  Evaluating the managed care implications of longer-acting basal insulin analog therapies. (Pubmed Central) -  Nov 24, 2019   
    This article spotlights the outcomes of the phase 3 clinical trials for these newer formulations, as well as more recent meta-analyses and real-world studies. It also highlights the implications for managed care plans as they move to add these insulins to their formularies.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Hypokalemia associated with mifepristone use in the treatment of Cushing's syndrome. (Pubmed Central) -  Nov 22, 2019   
    Patients on mifepristone require anticipation of toxicity, especially when the dose is escalated. The half-life of mifepristone is 85 h, requiring prolonged monitoring for toxicity, even after the medication is held.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
    Journal:  The quaternary structure of insulin glargine and glulisine under formulation conditions. (Pubmed Central) -  Nov 21, 2019   
    Insulin glargine in Lantus® and Toujeo® is present in a stable hexamer/dimer equilibrium, which is hardly affected by dilution with water down to 1 mg/ml insulin concentration. The results provide exclusive insight into the quaternary structure and thus the association/dissociation properties of the two insulin analogues in marketed formulations.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi
    Clinical effectiveness of insulin glargine 300 units/ml in insulin naïve T2DM patients - data from real-world setting (Poster Area) -  Nov 20, 2019 - Abstract #IDF2019IDF_1206;    
    Discussion In the real-world setting, in T2DM insulin naïve patients, U300 initiation is well accepted for the significant improvements in the glycemic control with no weight gain and no increase in the incidence of hypoglycemia. The distinct clinical advantages in our study as evident in the pragmatic setting may facilitate to reduce the clinical inertia and the barriers to insulin initiation.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    Comparison of insulin degludec and glargine U100 in type 1 diabetes patients prone to severe nocturnal hypoglycaemia (Poster Area) -  Nov 20, 2019 - Abstract #IDF2019IDF_1110;    
    No clinically significant differences in hypoglycaemia occurrence were observed between the insulin regimens during the day. Discussion In patients with type 1 diabetes prone to nocturnal severe hypoglycamia insulin degludec reduced the risk of clinically significant nocturnal symptomatic hypoglycaemia compared with insulin glargine U100.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Evaluation of higher starting dose of insulin glargine 100 U/mL in patients with T2DM: subgroup analysis by baseline FPG (Oral Poster Theatre 2) -  Nov 20, 2019 - Abstract #IDF2019IDF_820;    
    No differences in baseline characteristics between groups were observed, and at baseline 49.2% vs 49.7% had FPG levels of <11 mmol/L, respectively. At week 16, there was no difference between the higher or standard starting dose group in the proportion of patients with overall confirmed hypoglycaemia (blood glucose ≤3.9 mmol/L) in either the baseline FPG <11 mmol/L (estimated treatment difference ETD 0.89%; 95% CI −4.67%, 6.45%) or baseline FPG ≥11 mmol/L subgroups (ETD 2.99%; 95% Cl −2.13%, 8.11%).
  • ||||||||||  Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
    Trial completion:  A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants (clinicaltrials.gov) -  Nov 19, 2019   
    P1,  N=47, Completed, 
    Most doctors used a titration protocol with 2 U every 3-4 days (47.6%) and targeted a FPG of 100-130 mg/dL and a HbA1c between 6.5-7%. Active, not recruiting --> Completed
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Journal:  The West Palaearctic Dineura species, focussing on Sweden (Hymenoptera, Tenthredinidae). (Pubmed Central) -  Nov 18, 2019   
    dorsalis Enslin, 1915, Nematus posticus Förster, 1854, Nematus xanthocerus Hartig, 1840, Nematus xanthopus Zaddach, 1876, and Tenthredo (Allantus) stilata Klug, 1816. Distributions in the Fennoscandian countries are outlined, with particular reference to Sweden.